Loading stock data…
QDEL
$13.94-0.53 (-3.63%)
After Hours$13.94+0.00 (+0.00%)· Last close Jun 9
QuidelOrtho Corporation provides diagnostic testing solutions.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
QuidelOrtho Corporation in the Healthcare sector is trading at $13.94. Wall Street consensus targets $18.62 (4 analysts), implying a +33.6% move over the next 12 months. The stock is currently near its 52-week low of $9.92, remaining 39.7% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +33.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$13.94
Potential Downside
0%
Whystock Fair Value$13.94
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-65.40%
Volume
Today's trading volume
1.85M
Recent News
1 Stock Under $50 with Exciting Potential and 2 Facing Challenges
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
A Look At QuidelOrtho (QDEL) Valuation After Recent Share Price Rebound And Longer Term Weakness
Recent price action and business snapshot QuidelOrtho (QDEL) has drawn attention after a recent share price move, with the stock closing at US$14.33 and showing mixed performance across the past week, month, and past 3 months. For context, the company reports annual revenue of US$2.66b from diagnostic kits and equipment. It operates across North America, EMEA, China, JPAC, and Latin America, with reported net income currently in a loss of US$1.21b. See our latest analysis for QuidelOrtho. The...
QuidelOrtho (QDEL) Up 24.1% Since Last Earnings Report: Can It Continue?
QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
QuidelOrtho's Respiratory Exposure Remains a Key Near-Term Risk
QDEL's Q1 results show how a milder respiratory season can pressure revenue, margins and cash flow despite stable testing market share.
McIntyre Partnerships’ Analysis on QuidelOrtho Corporation (QDEL)
US-based investment company, McIntyre Partnerships, returned -19% gross and -20% net in the first quarter of 2026 compared to the Russell 2000 Value Index’s 5% return. A copy of the letter can be downloaded here. Since inception, the fund has returned ~14% gross and ~10% net per annum, surpassing the benchmark’s return of ~7% per […]